Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by distinct pathophysiological mechanisms leading to heterogeneous manifestations, including venous and arterial thrombosis. Despite the lack of specific markers of thrombosis risk in APS, some of the mechanisms responsible for thrombosis in APS may overlap with those of other thromboembolic diseases. Understanding these similarities is important for improving the assessment of thrombosis risk in APS. MicroRNAs (MiRNAs) are RNA molecules that regulate gene expression and may influence the autoimmune response and coagulation.
Purpose
In this scoping review we aimed to investigate shared miRNAs profiles associated with APS and other thromboembolic diseases as a means of identifying markers indicative of a pro-thrombotic profile among patients with APS.
Data collection and Results
Through a comprehensive search of scientific databases, 45 relevant studies were identified out of 1020 references. miRs-124-3p, 125b-5p, 125a-5p, and 17-5p, were associated with APS and arterial thrombosis, while miRs-106a-5p, 146b-5p, 15a-5p, 222-3p, and 451a were associated with APS and venous thrombosis. Additionally, miR-126a-3p was associated with APS and both arterial and venous thrombosis.
Conclusion
We observed that APS shares a common miRNAs signature with non-APS related thrombosis, suggesting that miRNA expression profiles may serve as markers of thrombotic risk in APS. Further validation of a pro-thrombotic miRNA signature in APS is warranted to improve risk assessment, diagnosis, and management of APS.
DabitJYValenzuela-AlmadaMOVallejo-RamosS, et al.Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep2022; 23: 85. DOI: 10.1007/s11926-021-01038-2.
2.
GasparPSciasciaSTektonidouMG. Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology2024; 63: si24–si36. DOI: 10.1093/rheumatology/kead571.
3.
Ruiz-IrastorzaGCuadradoMJRuiz-ArruzaI, et al.Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus2011; 20: 206–218. DOI: 10.1177/0961203310395803.
4.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis2006; 4: 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x.
Ruiz-IrastorzaGCrowtherMBranchW, et al.Antiphospholipid syndrome. Lancet2010; 376: 1498–1509. DOI: 10.1016/s0140-6736(10)60709-x.
7.
NiznikSRapoportMJAvneryO, et al.Patterns of recurrent thrombosis in primary antiphospholipid syndrome-multicenter, real-life long-term follow-up. Front Immunol2022; 13: 843718. DOI: 10.3389/fimmu.2022.843718.
8.
BradacovaPSlavikLUlehlovaJ, et al.Current promising biomarkers and methods in the diagnostics of antiphospholipid syndrome: a review. Biomedicines2021; 9: 166.
9.
ChaturvediSMcCraeKR. Clinical risk assessment in the antiphospholipid syndrome: current landscape and emerging biomarkers. Curr Rheumatol Rep2017; 19: 43. DOI: 10.1007/s11926-017-0668-2.
10.
SciasciaSSannaGMurruV, et al.GAPSS: the global anti-phospholipid syndrome score. Rheumatology2013; 52: 1397–1403. DOI: 10.1093/rheumatology/kes388.
11.
BakowBRYanekLCrowtherMA, et al.Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation. Thromb Res2024; 237: 88–93. DOI: 10.1016/j.thromres.2024.03.013.
12.
DufrostVRisseJReshetnyakT, et al.Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev2018; 17: 1011–1021. DOI: 10.1016/j.autrev.2018.04.009.
13.
LimW. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost2014; 40: 741–746. DOI: 10.1055/s-0034-1390003.
14.
TektonidouMGAndreoliLLimperM, et al.EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis2019; 78: 1296–1304. DOI: 10.1136/annrheumdis-2019-215213.
15.
ChighizolaCBWillisRMaioliG, et al.Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. Autoimmun Rev2024; 23: 103510. DOI: 10.1016/j.autrev.2023.103510.
Rosa dos SantosAPde Oliveira VazCHounkpeBW, et al.Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome. Lupus2022; 31: 1067–1077. DOI: 10.1177/09612033221101731.
18.
JacinthoBCMazetto FonsecaBMHounkpeBW, et al.Evaluation of a gene signature related to thrombotic manifestations in antiphospholipid syndrome. Front Med2023; 10: 1139906. DOI: 10.3389/fmed.2023.1139906.
BaekDVillénJShinC, et al.The impact of microRNAs on protein output. Nature2008; 455: 64–71. DOI: 10.1038/nature07242.
21.
SelbachMSchwanhäusserBThierfelderN, et al.Widespread changes in protein synthesis induced by microRNAs. Nature2008; 455: 58–63. DOI: 10.1038/nature07228.
22.
LeeRCFeinbaumRLAmbrosV. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell1993; 75: 843–854. DOI: 10.1016/0092-8674(93)90529-y.
23.
PasquinelliAEReinhartBJSlackF, et al.Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature2000; 408: 86–89. DOI: 10.1038/35040556.
FriedmanRCFarhKKBurgeCB, et al.Most mammalian mRNAs are conserved targets of microRNAs. Genome Res2009; 19: 92–105. DOI: 10.1101/gr.082701.108.
26.
WeberJABaxterDHZhangS, et al.The microRNA spectrum in 12 body fluids. Clin Chem2010; 56: 1733–1741. DOI: 10.1373/clinchem.2010.147405.
27.
CortezMACalinGA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expet Opin Biol Ther2009; 9: 703–711. DOI: 10.1517/14712590902932889.
28.
VickersKCPalmisanoBTShoucriBM, et al.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol2011; 13: 423–433. DOI: 10.1038/ncb2210.
29.
ArroyoJDChevilletJRKrohEM, et al.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A2011; 108: 5003–5008. DOI: 10.1073/pnas.1019055108.
30.
ZhangZZhangR. Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. Autoimmun Rev2015; 14: 854–863. DOI: 10.1016/j.autrev.2015.05.008.
31.
KotylaPJIslamMA. MicroRNA (miRNA): a new dimension in the pathogenesis of antiphospholipid syndrome (APS). Int J Mol Sci2020; 21: 21062076. DOI: 10.3390/ijms21062076.
32.
Pérez-SánchezLPatiño-TrivesAMAguirre-ZamoranoMÁ, et al.Characterization of antiphospholipid syndrome atherothrombotic risk by unsupervised integrated transcriptomic analyses. Arterioscler Thromb Vasc Biol2021; 41: 865–877. DOI: 10.1161/ATVBAHA.120.315346.
33.
TeruelRPérez-SánchezCCorralJ, et al.Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemostasis2011; 9: 1985–1992. DOI: 10.1111/j.1538-7836.2011.04451.x.
34.
Pérez-SánchezCAguirreMRuiz-LimónP, et al.Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol2017; 37: 1923–1932. DOI: 10.1161/atvbaha.117.309225.
35.
Pérez-SánchezCArias-de la RosaIAguirreM, et al.Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. Haematologica2018; 103: 908–918. DOI: 10.3324/haematol.2017.184416.
36.
Martinez-Martinez LaS-MFChacon-PerezMJNNJuarez-VicuñaY, et al.Serum chemokines and miRNA levels and its association with cumulative organ damage in patients with antiphospholipid syndrome: a bench to bedside study. Arthritis Rheumatol2018; 70(suppl 9): 172.
37.
Perez-SanchezCIMAguirre ZamoranoMRuiz-LimonP, et al.Circulating mirnas as potential disease biomarkers in antiphospholipid syndrome patients. Arthritis Rheumatol2015; 67(suppl 10): 2005.
38.
Pérez-SánchezCAguirreMARuiz-LimónP, et al.Atherothrombosis-associated microRNAs in antiphospholipid syndrome and systemic lupus erythematosus patients. Sci Rep2016; 6: 31375. DOI: 10.1038/srep31375.
39.
NagyDShaheenNHSelimHM, et al.MicroRNA-126 and 146a as potential biomarkers in systemic lupus erythematosus patients with secondary antiphospholipid syndrome. The Egyptian Rheumatologist2020; 42: 201–206. DOI: 10.1016/j.ejr.2020.05.002.
40.
Oliveira VazCVGMFerreiraALNascimento Silva VasconcelosPE, et al.Micrornas as potential biomarkers in thrombotic primary antiphospholipid syndrome. Res Pract Thromb Haemost2020; 4: 950–951. DOI: 10.1002/rth2.12393.
41.
D'AlessandraYDevannaPLimanaF, et al.Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J2010; 31: 2765–2773. DOI: 10.1093/eurheartj/ehq167.
42.
BadaczRKleczyńskiPLegutkoJ, et al.Expression of miR-1-3p, miR-16-5p and miR-122-5p as possible risk factors of secondary cardiovascular events. Biomedicines2021; 9: 1055. DOI: 10.3390/biomedicines9081055.
43.
ZhouXQiL. miR-124 is downregulated in serum of acute cerebral infarct patients and shows diagnostic and prognostic value. Clin Appl Thromb Hemost2021; 27: 10760296211035446. DOI: 10.1177/10760296211035446.
44.
HeX-WShiY-HLiuY-S, et al.Increased plasma levels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomes in acute ischaemic stroke patients receiving thrombolysis. Atherosclerosis2019; 289: 36–43. DOI: 10.1016/j.atherosclerosis.2019.08.002.
45.
TiedtSPrestelMKautzkyV, et al.Profiling of circulating miRNAS after human ischemic stroke with next-generation sequencing. Int J Stroke2015; 10: 40.
46.
NapoleãoPCabralLBPSelasM, et al.Stratification of ST-elevation myocardial infarction patients based on soluble CD40L longitudinal changes. Transl Res2016; 176: 95–104. DOI: 10.1016/j.trsl.2016.04.005.
47.
GiganteBPapaLByeA, et al.MicroRNA signatures predict early major coronary events in middle-aged men and women. Cell Death Dis2020; 11: 74. DOI: 10.1038/s41419-020-2291-9.
48.
LiLLiSWuM, et al.Early diagnostic value of circulating microRNAs in patients with suspected acute myocardial infarction. J Cell Physiol2019; 234: 13649–13658. DOI: 10.1002/jcp.28045.
49.
HromadkaMMotovskaZHlinomazO, et al.MiR-126-3p and MiR-223-3p as biomarkers for prediction of thrombotic risk in patients with acute myocardial infarction and primary angioplasty. J Personalized Med2021; 11: 508.
50.
Rodriguez-RiusALopezSMartinez-PerezA, et al.Identification of a plasma MicroRNA profile associated with venous thrombosis. Arterioscler Thromb Vasc Biol2020; 40: 1392–1399. DOI: 10.1161/atvbaha.120.314092.
51.
RossettiPGoldoniMPengoV, et al.MiRNA 126 as a new predictor biomarker in venous thromboembolism of persistent residual vein obstruction: a review of the literature plus a pilot study. Semin Thromb Hemost2021; 47: 982–991. DOI: 10.1055/s-0041-1726341.
52.
BaiXSJZhaoYZhangW, et al.Detection of MicroRNA-126 as a plasma biomarker for diagnosis of DVT. Res Pract Thromb Haemost2020; 4: 2292.
53.
WangXSundquistKSvenssonPJ, et al.Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenet2019; 11: 28. DOI: 10.1186/s13148-019-0627-z.
54.
StarikovaIJamalySSorrentinoA, et al.Differential expression of plasma miRNAs in patients with unprovoked venous thromboembolism and healthy control individuals. Thromb Res2015; 136: 566–572. DOI: 10.1016/j.thromres.2015.07.005.
55.
JinJWangCOuyangY, et al.Elevated miR-195-5p expression in deep vein thrombosis and mechanism of action in the regulation of vascular endothelial cell physiology. Exp Ther Med2019; 18: 4617–4624. DOI: 10.3892/etm.2019.8166.
56.
QinJLiangHShiD, et al.A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis2015; 39: 215–221. DOI: 10.1007/s11239-014-1131-0.
57.
ZhouXWuQHaoT, et al.Expression and diagnostic value of circulating miRNA-190 and miRNA-197 in patients with pulmonary thromboembolism. J Clin Lab Anal2021; 35: e23574. DOI: 10.1002/jcla.23574.
58.
StarikovaIHindbergKMartosL, et al.Plasma levels of miRNAs are associated with future risk of incident venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017; 1: 566–567. DOI: 10.1002/rth2.12012.
59.
MorelliVMStarikovaIHindbergK, et al.Plasma levels microRNAs and future risk of incident venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017; 1: 566–567. Conference Abstract. DOI: 10.1002/rth2.12012.
60.
DuXHongLSunL, et al.miR-21 induces endothelial progenitor cells proliferation and angiogenesis via targeting FASLG and is a potential prognostic marker in deep venous thrombosis. J Transl Med2019; 17: 270. DOI: 10.1186/s12967-019-2015-z.
61.
LiangHChenYLiH, et al.miR-22-3p suppresses endothelial progenitor cell proliferation and migration via inhibiting onecut 1 (OC1)/vascular endothelial growth factor A (VEGFA) signaling pathway and its clinical significance in venous thrombosis. Med Sci Mon Int Med J Exp Clin Res2020; 26: e925482. DOI: 10.12659/msm.925482.
62.
JiangZMaJWangQ, et al.Combination of circulating miRNA-320a/b and D-dimer improves diagnostic accuracy in deep vein thrombosis patients. Med Sci Mon Int Med J Exp Clin Res2018; 24: 2031–2037. DOI: 10.12659/msm.906596.
63.
YunheCCWZhengYWangQ. Circulating microRNA-423-5p serves as a potential diagnostic biomarker in elderly patients with deep-vein thrombosis. Int J Clin Exp Med2019; 7065–7073.
64.
WangXSundquistKElfJL, et al.Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. Thromb Haemostasis2016; 116: 328–336. DOI: 10.1160/th16-01-0071.
65.
ShazwanMSMuhammad AliffMAsral WirdaAA, et al.MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis. Malays J Pathol2016; 38: 273–283.
66.
GongJYangYWangJ, et al.Expression of miR-93-5p as a potential predictor of the severity of chronic thromboembolic pulmonary hypertension. BioMed Res Int2021; 2021: 6634417. DOI: 10.1155/2021/6634417.
67.
KrepelkovaIMrackovaTIzakovaJ, et al.Evaluation of miRNA detection methods for the analytical characteristic necessary for clinical utilization. Biotechniques2019; 66: 277–284. DOI: 10.2144/btn-2019-0021.
68.
ChafinCBRegnaNLHammondSE, et al.Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharm2013; 17: 894–906. DOI: 10.1016/j.intimp.2013.09.013.
69.
Kabiri RadHMazaheriMDehghani FirozabadiA. Relative expression of PBMC MicroRNA-133a analysis in patients receiving warfarin after mechanical heart valve replacement. Avicenna J Med Biotechnol (AJMB)2018; 10: 29–33.
70.
LongHWangXChenY, et al.Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett2018; 428: 90–103. DOI: 10.1016/j.canlet.2018.04.016.
71.
PierouliKPapageorgiouLMitsisT, et al.Role of microRNAs and long non-coding RNAs in glucocorticoid signaling (review). Int J Mol Med2022; 50: 147. DOI: 10.3892/ijmm.2022.5203.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
